We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.
- Authors
Kindler, H L; Richards, D A; Garbo, L E; Garon, E B; Stephenson, J J, Jr; Rocha-Lima, C M; Safran, H; Chan, D; Kocs, D M; Galimi, F; McGreivy, J; Bray, S L; Hei, Y; Feigal, E G; Loh, E; Fuchs, C S
- Abstract
We evaluated the efficacy and safety of ganitumab (a mAb antagonist of insulin-like growth factor 1 receptor) or conatumumab (a mAb agonist of human death receptor 5) combined with gemcitabine in a randomized phase 2 trial in patients with metastatic pancreatic cancer.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Vol 23, Issue 11, p2834
- ISSN
1569-8041
- Publication type
Journal Article
- DOI
10.1093/annonc/mds142